NCT02763787View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

June 30, 2000

Study Completion Date

June 30, 2000

Conditions
Parkinson's Disease
Interventions
DRUG

BIA 3-202

single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)

DRUG

Placebo

Identical placebo

Trial Locations (1)

SE1 1YR

Guy's Drug Research Unit (GDRU), London

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02763787 - Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 | Biotech Hunter | Biotech Hunter